Esther Stern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Esther Stern has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Auguste Genovesio
Computational Bioimaging and Bioinformatics, IBENS, École normale supérieure, CNRS, INSERM, Université PSL
32 shared publications - Charles Al Zreibi
Department of Thoracic Surgery and Lung Transplantation, Hôpital Européen Georges-Pompidou, Assistance Publique—Hôpitaux de Paris, Université Paris Cité , 75908 Paris
32 shared publications - Christophe Blanquart
Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
32 shared publications - Clément Meiller
INSERM, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, Functional Genomics of Solid Tumors, Paris, France
32 shared publications - Didier Jean
INSERM, Universite Paris Cite, Sorbonne Universite, Centre de Recherche des Cordeliers, F-75006 Paris, France
32 shared publications - Elaine Del Nery
Biophenics Laboratory, Institut Curie, PSL Research University, Department of Translational Research, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France
32 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S20 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Dose-response screening of 20 drugs, including pemetrexed and cisplatin, alone or in combination.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S20 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Dose-response screening of 20 drugs, including pemetrexed and cisplatin, alone or in combination.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Consensus matrix of the clustering based on methylome data.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Consensus matrix of the clustering based on methylome data.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Contribution of epithelial-to-mesenchymal transition (EMT) to cell line heterogeneity.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Contribution of epithelial-to-mesenchymal transition (EMT) to cell line heterogeneity.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Distribution of the genetic alterations in the Hippo core pathway plus NF2, SWI/SNF chromatin remodelling complex pathway and homologous recombination repair pathway.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Distribution of the genetic alterations in the Hippo core pathway plus NF2, SWI/SNF chromatin remodelling complex pathway and homologous recombination repair pathway.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Histologic and molecular characteristics of transcriptome subtypes.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Histologic and molecular characteristics of transcriptome subtypes.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S21 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Classification of the drugs based on their sensitivity profiles across cell lines.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S21 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Classification of the drugs based on their sensitivity profiles across cell lines.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Effect of genetic alterations on TERT gene expression.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Effect of genetic alterations on TERT gene expression.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Consensus matrix of the clustering based on transcriptome data.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Consensus matrix of the clustering based on transcriptome data.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S19 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Large-scale and validation drug screens.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S19 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
Large-scale and validation drug screens.